MX347808B - Variantes de plasminogeno y plasmina. - Google Patents

Variantes de plasminogeno y plasmina.

Info

Publication number
MX347808B
MX347808B MX2014001707A MX2014001707A MX347808B MX 347808 B MX347808 B MX 347808B MX 2014001707 A MX2014001707 A MX 2014001707A MX 2014001707 A MX2014001707 A MX 2014001707A MX 347808 B MX347808 B MX 347808B
Authority
MX
Mexico
Prior art keywords
plasminogen
plasmin
variants
plasmin variants
compositions
Prior art date
Application number
MX2014001707A
Other languages
English (en)
Other versions
MX2014001707A (es
Inventor
Reinier Zwaal Richard
Original Assignee
Thrombogenics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thrombogenics Nv filed Critical Thrombogenics Nv
Publication of MX2014001707A publication Critical patent/MX2014001707A/es
Publication of MX347808B publication Critical patent/MX347808B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a variantes de plasminógeno y plasmina que comprenden una o más mutaciones puntuales en el dominio catalítico, las cuales reducen o previenen la destrucción autocatalítica de la actividad de proteasa de plasmina. También se describen composiciones, usos y métodos para usar tales variantes de plasminógeno y plasmina.
MX2014001707A 2011-08-12 2012-08-13 Variantes de plasminogeno y plasmina. MX347808B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161522817P 2011-08-12 2011-08-12
EP12161185 2012-03-26
PCT/EP2012/065832 WO2013024074A1 (en) 2011-08-12 2012-08-13 Plasminogen and plasmin variants

Publications (2)

Publication Number Publication Date
MX2014001707A MX2014001707A (es) 2014-04-30
MX347808B true MX347808B (es) 2017-05-15

Family

ID=47714799

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014001707A MX347808B (es) 2011-08-12 2012-08-13 Variantes de plasminogeno y plasmina.

Country Status (12)

Country Link
US (1) US9644196B2 (es)
EP (1) EP2741767A1 (es)
JP (1) JP6000353B2 (es)
KR (1) KR20140064841A (es)
CN (1) CN103764163A (es)
AU (1) AU2012296884B2 (es)
BR (1) BR112014003109A2 (es)
CA (1) CA2844644A1 (es)
IL (1) IL230821A0 (es)
MX (1) MX347808B (es)
RU (1) RU2604810C2 (es)
WO (1) WO2013024074A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120050442A (ko) 2009-07-10 2012-05-18 쓰롬보제닉스 엔.브이. 플라스미노겐 및 플라스민의 변이체
ES2534911T3 (es) 2009-08-28 2015-04-30 Thrombogenics N.V. Uso de plasmina para el tratamiento de fallo de filtración después de trabeculectomía
CA2823491A1 (en) 2011-01-05 2012-07-12 Thrombogenics Nv Plasminogen and plasmin variants
US9644196B2 (en) 2011-08-12 2017-05-09 Thrombogenics Nv Plasminogen and plasmin variants
RU2711989C2 (ru) * 2014-12-19 2020-01-23 Прометик Байо Терапьютикс, Инк. Фармацевтическая композиция, содержащая плазминоген, и ее применение
CN106609266B (zh) * 2015-10-27 2020-09-11 江苏恒瑞医药股份有限公司 一种微纤溶酶原变体及通过其得到的微纤溶酶变体
TW201722464A (zh) 2015-11-10 2017-07-01 波麥堤克生化科學有限公司 用於傷口癒合之纖維蛋白溶酶原給藥方案
DK3391902T3 (da) 2015-12-18 2023-11-20 Talengen Int Ltd Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati
US11400142B2 (en) 2015-12-18 2022-08-02 Talengen International Limited Treatment of diabetic nerve injury comprising administering plasminogen
CN108463240A (zh) 2015-12-18 2018-08-28 泰伦基国际有限公司 一种预防或治疗糖尿病性视网膜病变的方法
WO2017101873A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防或治疗放射性和化学性损伤的方法
CN106890322A (zh) * 2015-12-18 2017-06-27 深圳瑞健生命科学研究院有限公司 一种预防或治疗放射性和化学性损伤的方法
EP3395354B1 (en) 2015-12-18 2024-05-22 Talengen International Limited Plasminogen for use in treating diabetic nephropathy
TW201829448A (zh) 2016-12-15 2018-08-16 大陸商深圳瑞健生命科學硏究院有限公司 纖溶酶原在製備預防或治療肥胖症及疾病倂發的肥胖的藥物中的用途
CN108210895A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防动脉粥样硬化及其并发症的药物及其用途
US11389515B2 (en) 2016-12-15 2022-07-19 Talengen International Limited Method for mitigating heart disease
CN108210917A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 一种预防和治疗肥胖症的方法和药物
EP3556384B1 (en) 2016-12-15 2024-04-10 Talengen International Limited Plasminogen for use in treating diabetes
TWI684459B (zh) * 2016-12-15 2020-02-11 大陸商深圳瑞健生命科學研究院有限公司 一種治療動脈粥樣硬化及其併發症的方法
US11759505B2 (en) 2017-03-09 2023-09-19 Previpharma Consulting Gmbh Preparing and use of Glu-plasminogen from blood fractions

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3208908A (en) 1961-11-16 1965-09-28 Parke Davis & Co Fibrinolysin-desoxyribonuclease for enzymatic debridement
US4122158A (en) 1976-09-23 1978-10-24 Alza Corporation Topical therapeutic preparations
NZ191320A (en) 1978-09-07 1982-09-14 Beecham Group Ltd In vivo fibrinolytic enzyme having active site blocked by hydrolytically removable group pharmaceutical compositions
IT1194135B (it) 1981-01-05 1988-09-14 Novo Industri As Composizioni di plasmina stabilizzata e metodo per la loro preparazione
US4774087A (en) 1987-08-14 1988-09-27 Northwestern University Micro-size fibrinolytic plasmin
JPH05500748A (ja) 1989-05-01 1993-02-18 ザ　ユニバーシティ　オブ　ノートル　ダム　デュ　ラック 真核細胞系でのヒトプラスミノーゲンの発現方法および物質
US5087572A (en) 1989-12-01 1992-02-11 Genentech, Inc. Dna encoding human plasminogen modified at the cleavage site
GB8927722D0 (en) 1989-12-07 1990-02-07 British Bio Technology Proteins and nucleic acids
AT402367B (de) 1990-10-11 1997-04-25 Immuno Ag Pharmazeutische zubereitung auf basis von lys-plasminogen
US5288489A (en) 1991-08-28 1994-02-22 Orion Therapeutic Systems, Inc. Fibrinolysis and fibrinogenolysis treatment
IT1260468B (it) 1992-01-29 1996-04-09 Metodo per mantenere l'attivita' di enzimi proteolitici modificati con polietilenglicole
US5304118A (en) 1992-12-16 1994-04-19 Trese Michael T Method for performing a vitrectomy on an eye
US5520912A (en) 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
DE4411143C2 (de) 1994-03-30 1996-08-01 Immuno Ag Thrombosemittel
WO1997001631A1 (fr) 1995-06-26 1997-01-16 Daiichi Pure Chemicals Co., Ltd. Solution stable de plasmine
WO1997041824A2 (en) 1996-05-03 1997-11-13 Abbott Laboratories Antiangiogenic peptides derived from plasminogen
EP1117437B1 (en) 1998-09-29 2006-12-27 Leuven Research & Development vzw Use of compounds that reduce alpha2-antiplasmin in vivo for the preparation of a composition for the treatment of ischemic stroke
US6733750B1 (en) 1999-03-09 2004-05-11 Minu, L.L.C. Process and composition for inducing posterior vitreous detachment
US20040081643A1 (en) 1999-03-09 2004-04-29 Peyman Gholam A. Process for inhibiting vascular proliferation in the eye
US6899877B2 (en) 1999-03-09 2005-05-31 Minu, L.L.C. Process for generating plasmin in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina
US6585972B2 (en) 1999-03-09 2003-07-01 Gholam A. Peyman Process for crosslinking of collagen in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina
ES2283308T3 (es) 1999-07-14 2007-11-01 D. Collen Research Foundation Vzw Anticuerpo monoclonal para el factor viii, que incluso cuando esta presente en exceso molar inactiva el factor viii solo en parte y metodo para producir dicho anticuerpo.
US6440414B1 (en) 1999-10-01 2002-08-27 Amgen Inc. Pharmaceutical compositions of fibrinolytic agent
US6355243B1 (en) 1999-11-13 2002-03-12 Bayer Corporation Method of thrombolysis by local delivery of active plasmin
US7544500B2 (en) 1999-11-13 2009-06-09 Talecris Biotherapeutics, Inc. Process for the production of a reversibly inactive acidified plasmin composition
US6969515B2 (en) 1999-11-13 2005-11-29 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
US6964764B2 (en) 1999-11-13 2005-11-15 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
CA2400497A1 (en) 2000-02-08 2001-08-16 Northwestern University Methods and compositions for generating angiostatin
DE60131450T2 (de) 2000-12-21 2008-10-16 Thrombogenics N.V. Hefeexpressionsvektor und verfahren zur herstellung eines rekombinanten proteins durch expression in einer hefezelle
US20020139378A1 (en) 2001-03-28 2002-10-03 Trese Michael T. Method for creating a separation of posterior cortical vitreous from the retina of the eye
DE10153601A1 (de) 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall
US20040009212A1 (en) 2002-01-30 2004-01-15 Pharma Power Biotec Co. Ltd. Mucoadhesive thermoresponsive medicament-carrier composition
US7776026B2 (en) 2002-02-06 2010-08-17 Nuvue Technologies, Inc. Method for vitreous liquefaction
CA2475277A1 (en) 2002-02-06 2003-08-14 Trommsdorff Gmbh & Co. Kg Arzneimittel Method for producing recombinant proteins in micro-organisms
US6787135B2 (en) 2002-03-13 2004-09-07 William Beaumont Hospital Modification of vitreal matrix metalloproteinase activity
US20040235115A1 (en) 2002-11-18 2004-11-25 Reed Guy L. Compositions and methods for treating thrombotic disorders
GB0228409D0 (en) 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
EP1706079B1 (en) 2003-08-14 2013-02-20 ThromboGenics N.V. Antibodies against factor viii with modified glycosylation in the variable region
AU2005212431B2 (en) 2004-02-11 2010-07-15 Synthon Biopharmaceuticals B.V. Expression of plasminogen and microplasminogen in duckweed
CN1253560C (zh) 2004-03-01 2006-04-26 宁夏大学 组织型纤溶酶原激活剂缺失/点突变体基因转染细胞株
EP2246417B1 (en) 2004-04-22 2015-01-21 Grifols Therapeutics Inc. Recombinantly modified plasmin
US20060257391A1 (en) 2005-05-11 2006-11-16 Bausch & Lomb Incorporated Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
WO2007047874A2 (en) 2005-10-20 2007-04-26 Talecris Biotherapeutics, Inc. Recombinantly modified plasmin
US20070134230A1 (en) 2005-12-13 2007-06-14 Jani Dharmendra M Method for prolonging activity of autodegradable enzymes
US20070134231A1 (en) 2005-12-13 2007-06-14 Jani Dharmendra M Method for prolonging activity of autodegradable enzymes and compositions thereof
US20070196350A1 (en) 2006-02-22 2007-08-23 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment
US20070212358A1 (en) 2006-03-10 2007-09-13 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment
WO2008026999A2 (en) 2006-08-28 2008-03-06 Omnio Healer Ab Candidates against infection
WO2008054592A2 (en) 2006-09-29 2008-05-08 Proteomtech, Inc. Methods for production of recombinant plasminogen and plasmin polypeptides
AU2008331545B2 (en) 2007-11-29 2014-01-16 Grifols Therapeutics Inc. Recombinantly modified plasmin
WO2009073457A1 (en) 2007-11-30 2009-06-11 Bausch & Lomb Incorporated Methods and compositions for the rescue of a filtering bleb
KR20120050442A (ko) * 2009-07-10 2012-05-18 쓰롬보제닉스 엔.브이. 플라스미노겐 및 플라스민의 변이체
CA2823491A1 (en) 2011-01-05 2012-07-12 Thrombogenics Nv Plasminogen and plasmin variants
US9644196B2 (en) 2011-08-12 2017-05-09 Thrombogenics Nv Plasminogen and plasmin variants

Also Published As

Publication number Publication date
JP6000353B2 (ja) 2016-09-28
AU2012296884A1 (en) 2013-05-02
JP2014525235A (ja) 2014-09-29
RU2014108489A (ru) 2015-09-10
NZ622210A (en) 2015-12-24
RU2604810C2 (ru) 2016-12-10
EP2741767A1 (en) 2014-06-18
KR20140064841A (ko) 2014-05-28
MX2014001707A (es) 2014-04-30
CA2844644A1 (en) 2013-02-21
CN103764163A (zh) 2014-04-30
WO2013024074A1 (en) 2013-02-21
US9644196B2 (en) 2017-05-09
IL230821A0 (en) 2014-03-31
AU2012296884B2 (en) 2015-02-05
US20140205588A1 (en) 2014-07-24
BR112014003109A2 (pt) 2017-02-21

Similar Documents

Publication Publication Date Title
MX347808B (es) Variantes de plasminogeno y plasmina.
MX2013007791A (es) Variantes de plasminogeno y plasmina.
MX2012000475A (es) Variantes de plasminogeno y plasmina.
MX2018016021A (es) Composiciones y metodos que comprenden variante de enzima lipolitica.
MX338925B (es) Composiciones y metodos que comprenden variantes de proteasa serina.
MX2016000719A (es) Composiciones y metodos que comprenden una variante de enzima lipolitica.
MX356282B (es) Composiciones y metodos que comprenden variantes de proteasa.
MX336737B (es) Composiciones y metodos que comprenden variantes de proteasa serina.
EA030252B9 (ru) Варианты полипептидов ph20, композиции на их основе и их применение
MA33894B1 (fr) Procedes d'administration therapeutique de la pirferidone
JO3002B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
SG10201903119QA (en) Polypeptide vaccine
WO2012125544A3 (en) Necroptosis inhibitors and methods of use therefor
IN2012DN02471A (es)
TW201611843A (en) Methods of treatment with arginine deiminase
MX355128B (es) Péptidos inhibidores de bace1 y uso de los mismos para el tratamiento de enfermedades o trastornos neurológicos.
HRP20170987T1 (hr) Fibrinolitički pripravci koji sadrže bromelain i natokinazu za sprječavanje i liječenje flebotrombotičkih stanja
WO2014160775A8 (en) Compositions and methods for the treatment of malaria
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
EA201390532A1 (ru) Композиции сульфамидых ингибиторов ns3, содержащие витамин е
MX338553B (es) Procesos para la preparacion de enaminas.
MX2013006192A (es) Procesos para la preparacion de enaminas.
UA105703C2 (uk) 7-бром-5-феніл-3-ариламіно-1,2-дигідро-3н-1,4-бенздіазепін-2-они як анальгетичні агенти
UA96649C2 (ru) Применение глюкозамина гидрохлорида как средства фригопротекторной действия

Legal Events

Date Code Title Description
FG Grant or registration